Keros Therapeutics (KROS) Interest Expenses (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Interest Expenses came in at $98.0 million in Q4 2025, up 10668.24% YoY from N/an in Q4 2024, and up 1407.55% on a QoQ basis from $6.5 million in Q3 2025.
Keros Therapeutics (KROS) Interest Expenses (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Interest Expenses data on file, last reported at $98.0 million in Q4 2025.
- Quarterly Interest Expenses rose 10668.24% year-over-year to $98.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $98.0 million (up 13088.56% YoY) and the FY2025 annual result came in at $98.0 million, down 34.69% from the prior year.
- Interest Expenses grew to $98.0 million in Q4 2025, from $6.5 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $134.6 million in Q1 2024 to a low of -$880000.0 in Q4 2023.
- A 5-year average of $40.5 million and a median of $32.0 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses slumped 513.15% — and 2024, when it jumped 26820.0%.
- Tracing KROS's Interest Expenses over 5 years: stood at $1000.0 in 2021, then soared by 21200.0% to $213000.0 in 2022, then tumbled by 513.15% to -$880000.0 in 2023, then surged by 203.41% to $910000.0 in 2024, then jumped by 10668.24% to $98.0 million in 2025.
- The last three Interest Expenses figures came in at $98.0 million (Q4 2025), $6.5 million (Q3 2025), and $5.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Keros Therapeutics | 217.21 Mn | -40.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.40 Mn |
| Jun 30, 2026 | 3.40 Mn |
| Dec 31, 2025 | 97.99 Mn |
| Dec 31, 2025 | 97.99 Mn |
| Sep 30, 2025 | 6.50 Mn |
| Sep 30, 2025 | 6.50 Mn |
| Jun 30, 2025 | 5.40 Mn |
| Jun 30, 2025 | 5.40 Mn |
| Mar 31, 2025 | 4.60 Mn |
| Mar 31, 2025 | 4.60 Mn |
| Dec 31, 2024 | 910,000.00 |
| Dec 31, 2024 | 910,000.00 |
| Sep 30, 2024 | 93.50 Mn |
| Sep 30, 2024 | 93.50 Mn |
| Jun 30, 2024 | 54.40 Mn |
| Jun 30, 2024 | 54.40 Mn |
| Mar 31, 2024 | 134.60 Mn |
| Mar 31, 2024 | 134.60 Mn |
| Dec 31, 2023 | -880,000.00 |
| Dec 31, 2023 | -880,000.00 |